BHVN - NYSE

Biohaven Ltd.

BHVN·NYSE

$11.35

+12%

HealthcareBiotechnology

Biohaven Ltd. is a clinical-stage biopharmaceutical company. The Company focuses on development of therapies for neurological and immunoscience diseases that can change current treatment paradigms.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$1.20B

EPS-6.8600

P/E Ratio-1.65

Earnings Date08/10/2026

bhvn

Cash at End of Period

Last Annual Value

232.78M

3-Year CAGR

-1%

5-Year CAGR

23%

10-Year CAGR

Adjust for Inflation

Biohaven Ltd. Competitors Analysis of Cash at End of Period

BHVN · NYSE

Company	Cash at End of Period	CAGR 3Y	CAGR 5Y	CAGR 10Y
Biohaven Ltd. NYSE:BHVN	232.78M	-2.6%	24.7%	N/A
Intellia Therapeutics, Inc. NASDAQ:NTLA	202.79M	-5.5%	10.1%	-2.9%
Immunome, Inc. NASDAQ:IMNM	653.69M	87.7%	67.7%	N/A
Vera Therapeutics, Inc. NASDAQ:VERA	354.73M	98.0%	34.7%	N/A
Sionna Therapeutics, Inc. NASDAQ:SION	59.41M	14.6%	N/A	N/A
Zenas BioPharma, Inc. NASDAQ:ZBIO	110.64M	24.8%	N/A	N/A
Xeris Biopharma Holdings, Inc. NASDAQ:XERS	115.06M	17.1%	-1.8%	13.6%
Celldex Therapeutics, Inc. NASDAQ:CLDX	28.87M	-6.0%	-5.9%	-3.8%

Biohaven Ltd. Fair Value Envelope

BHVN · NYSE

Our analysis suggests that BHVN has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $11.35, this represents a potential HIDDEN relative to our calculated worth for Biohaven Ltd..

HIDDEN

Intrinsic Value

Current Price: $11.35

Related Guides

Blog Categories

Continue your BHVN research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.